Results 91 to 100 of about 2,650 (185)
Ophthalmology and TherapyIntroduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular ...
Federico Beretta +6 more
doaj +1 more source
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice [PDF]
, 2021 Eandi, C. M.
core +1 more source
Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents [PDF]
Long-lasting anti-vascular endothelial growth factor (anti-VEGF) agents have become an option to reduce treatment frequency, with ongoing research exploring optimal responses and safety profiles. This review delves into molecular targets, pharmacological
Abdolrahimzadeh, Barmak +5 more
core +1 more source
Investigating the feasibility of selective anti-VEGF delivery to the retina using a microinvasive approach [PDF]
Background: Retinal therapeutics has been revolutionized by anti-vascular endothelial growth factor (VEGF) therapies, whereby intravitreal injection is the accepted delivery method.
Arai, Mizuho +9 more
core +2 more sources
Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration:a systematic review [PDF]
Background: To systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings.
Grauslund, Jakob +4 more
core +1 more source
Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration – A systematic review and meta-analysis [PDF]
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the world and anti-vascular endothelial growth factor (VEGF) injections have been the standard of care for the wet/neovascular variant since 2004.
Hoven, Erlend +3 more
core +1 more source
Scientific ReportsThis study aimed to evaluate the incidence of clinically significant intraocular inflammation (csIOI) after treatment with intravitreal injection (IVI) of brolucizumab and identify csIOI risk factors.
Hyo Song Park +7 more
doaj +1 more source
Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration. [PDF]
PURPOSE: To report our real-world experience using intravitreal faricimab, a novel anti-vascular endothelial growth factor (anti-VEGF) therapy, in eyes with neovascular age-related macular degeneration (nAMD) previously treated with other anti-VEGF ...
Emami-Naeini, Parisa +6 more
core +1 more source